Kenneth A. Berlin has been appointed president and chief executive officer, Rosetta Genomics, Ltd., and has been recommended to serve on the company’s board of directors.

Mr. Berlinpreviously served as worldwide general manager at Veridex, LLC, a Johnson & Johnson company. Under his leadership the organization grew to more than 100 employees, and he spearheaded the launch of three cancer diagnostic products. Mr. Berlin joined J&J in 1994 and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions. He then held positions of increasing responsibility within J&J and a number of its subsidiary companies.

“Ken is a proven business leader whose background, accomplishments and commercialization experience in the novel diagnostics space are particularly well-suited for Rosetta Genomics at this time,” said Yoav Chelouche, chairman of the board of directors. “We have commercialized three microRNA diagnostic tests and have licensed or formed distribution agreements with six separate parties on five continents for these tests. As we further develop the markets for our paraffin-based microRNA diagnostic tests and pursue avenues to leverage our platform technology, we expect that Rosetta will benefit from Ken’s strong leadership, negotiating and alliance management skills as well as his portfolio management experience.”

News from our sister sites